Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Informa delivers 'further strong growth' in Q1

(Sharecast News) - Publishing and exhibitions group Informa said on Thursday that it had delivered "further strong growth" in Q1, with continuing forward visibility through subscriptions, recurring revenues and forward booked contracts. Informa said total group underlying revenues grew 7.6% in Q1, with "strong performances" across its live B2B events portfolio and in academic markets.

FY revenues of more than £2.5bn were said to have already been traded, booked or committed through subscriptions, recurring exhibitor revenues and forward booked contracts, marking 61% of annual target revenues, pacing ahead of 2024.

The FTSE 100-listed firm also noted that it had experienced "strong demand" across all regions in Q1 and continued its market-leading outperformance in India, Middle East and Africa.

Looking ahead, Informa reiterated its FY guidance for group underlying revenues of more than 5%, as well as its revenue target of £4.1bn and expectation for double-digit adjusted earnings growth.

Chief executive Stephen Carter said: "The Informa Group continues to deliver strong underlying growth in both Live B2B Events and Academic Markets."

"Specialist brands in Specialist markets, annual/multi-year subscriptions, forward booked revenues, and leading positions in faster-growing geographies, underpin the Informa growth platform."

As of 0840 BST, Informa shares were up 2.61% at 747.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.